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Abstract
Background: Acute encephalopathy includes rapid deterioration and has a poor prognosis. Early intervention is
essential to prevent progression of the disease and subsequent neurologic complications. However, in the acute
period, true encephalopathy cannot easily be differentiated from febrile seizures, especially febrile seizures of the
complex type. Thus, an early diagnostic marker has been sought in order to enable early intervention. The purpose
of this study was to identify a novel marker candidate protein differentially expressed in the cerebrospinal fluid
(CSF) of children with encephalopathy using proteomic analysis.
Methods: For detection of biomarkers, CSF samples were obtained from 13 children with acute encephalopathy
and 42 children with febrile seizure. Mass spectral data were generated by surface-enhanced laser desorption/
ionization time-of-flight mass spectrometry (SELDI-TOF MS) technology, which is currently applied in many fields of
biological and medical sciences. Diagnosis was made by at least two pediatric neurologists based on the clinical
findings and routine examinations. All specimens were collected for diagnostic tests and the remaining portion of
the specimens were used for the SELDI-TOF MS investigations.
Results: In experiment 1, CSF from patients with febrile seizures (n = 28), patients with encephalopathy (n = 8)
(including influenza encephalopathy (n = 3), encephalopathy due to rotavirus (n = 1), human herpes virus 6 (n =
1)) were used for the SELDI analysis. In experiment 2, SELDI analysis was performed on CSF from a second set of
febrile seizure patients (n = 14) and encephalopathy patients (n = 5). We found that the peak with an m/z of 4810
contributed the most to the separation of the two groups. After purification and identification of the 4.8-kDa
protein, a 4.8-kDa proteolytic peptide fragment from the neurosecretory protein VGF precursor (VGF4.8) was
identified as a novel biomarker for encephalopathy.
Conclusions: Expression of VGF4.8 has been reported to be decreased in pathologically degenerative changes
such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, and encephalopathy.
Thus, the VGF4.8 peptide might be a novel marker for degenerative brain conditions.
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Acute encephalopathy is characterized by sudden onset
of high fever, lethargy, convulsions, and loss of con-
sciousness, with poor prognoses associated with virus
infections including causativ ev i r u s e ss u c ha st h ei n f l u -
enza virus and other etiologies [1-3]. Given that ence-
phalopathy leads to rapid deterioration and a poor
prognosis, early intervention is essential in order to pre-
vent progression of the disease and neurologic compli-
cations. However, in the acute period, true
encephalopathy cannot easily be differentiated from feb-
rile seizures, especially febrile seizures of the complex
type [4-7]. Thus, an early diagnostic marker has been
sought to enable early intervention in the disease.
Surface-enhanced laser desorption/ionization time-of-
light mass spectrometry (SELDI-TOF MS) technology is
currently applied in many fields of the biological and
medical sciences, and has been extensively reviewed [8].
SELDI is a chromatography-based mass spectrometry
(MS) platform in which proteins are selectively absorbed
onto a chemically modified ProteinChip (Bio-Rad
Laboratories, Inc., Hercules, CA, USA) array surface
prior to the addition of an energy-absorbing matrix
solution. The absorbed proteins are subjected to a
pulsed laser beam to produce gas-phase ions that are
accelerated into a field-free flight tube and separated
according to their mass-dependent velocities (mass/
charge: m/z). The ability of the selective array surfaces
to retain subsets of the proteome allows the analysis of
complex biological specimens such as serum, cell lysates,
and cerebrospinal fluid. In the present study, SELDI-
TOF MS was employed to identify a possible biomarker
in cerebrospinal fluid for acute encephalopathy and a
proteolytic peptide fragment from the neurosecretory
protein VGF precursor was identified as a novel biomar-
ker for encephalopathy.
Methods
Definitions of acute encephalopathy and febrile seizures
Because acute encephalopathy is a generic term for
acute brain dysfunction usually preceded by infection,
encephalopathy related to infection as acute encephalo-
pathy was not excluded [1,2].
Acute encephalopathy: The criteria for diagnosis of
encephalopathy were 1) impaired consciousness, 2) signs
of increased intracranial pressure due to brain edema, 3)
convulsions and seizures, 4) slow activity on electroen-
cephalography lasting more than 24 h after acute onset,
and 5) no bacteria or fungi on CSF culture [1,2,9].
Febrile seizures: Febrile seizures were defined as 1) sei-
zures with fever and impaired consciousness lasting less
than 24 h without neurological sequelae, 2) usually occur-
ring between 3 months and 5 years of age, and 3) without
evidence of intracranial infection or defined cause [4-7,9].
Subjects
Two studies were performed on cerebrospinal fluid
( C S F )f r o mp a t i e n t sa tt h eD e p a r t m e n to fP e d i a t r i c s ,
Nippon Medical School Chiba Hokusoh Hospital. In an
initial study (experiment 1) for discovering the new,
novel biomarkers, CSF from febrile seizure subjects (n =
28) and patients with encephalopathy (n = 8), including
influenza encephalopathy (n = 3), encephalopathy due
to rotavirus (n = 1), human herpes virus 6 (n = 1) were
used for the SELDI analysis. In a second study (experi-
ment 2) for validating the markers, SELDI analysis was
performed on CSF from a second set of febrile seizure
subjects (n = 14) and encephalopathy patients (n = 5).
Diagnosis was made by at least two pediatric neurolo-
gists based on clinical findings, routine examinations
described above, and lumber puncture performed at the
onset of illness.
All CSF specimens were collected for diagnostic tests
and the remaining portions of the specimens were used
for SELDI-TOF MS investigation. Following collection,
samples were centrifuged at 1500 rpm for 5 min to
remove cells, divided into aliquots and immediately fro-
z e no nd r yi c ea n ds t o r e da t- 8 0 ° C .T h eI n s t i t u t i o n a l
Review Board at Nippon Medical School, Chiba Hoku-
soh Hospital approved the collection and investigation
of samples and written informed consent was obtained
from all subjects.
Proteomic technology
SELDI-TOF MS is a system that enables rapid protein
profiling, identification, and characterization from crude
biological samples by selective capture of subclasses of
proteins with specific physical or biochemical character-
istics. The molecular weight as well as the quantity of
individual proteins absorbed on each ProteinChip array
is then directly assessed by a time-of-flight mass spec-
trometer, generating quantitative protein mass profiles
for individual CSF specimens. Comparative protein
expression profile analysis highlights any CSF protein
species which are aberrantly expressed in the CSF of
encephalopathy patients compared to febrile seizure
subjects.
Before analysis of the CSF, experiments were
designed to optimize the ProteinChip array conditions
for the SELDI-TOF MS proteomics tests. Three chip
types, Q10 (strong anion exchange surface), CM10
(weak cation exchange surface), and IMAC30 (metal
binding surface) (Bio-Rad), were tested along with a
variety of binding/washing conditions, including pH
4.5, 6.5, and 8.0 binding/washing buffers. The Pro-
teinChip array condition that produced optimal results
was the Q10 ProteinChip array with 50 mM Tris-HCl,
pH 8.0 binding and wash steps, and was therefore used
in this study.
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compatible bioprocessor was used. The ProteinChip
array spot surface was equilibrated with wash buffer (50
mM Tris-HCl, pH 8.0) for 10 min prior to use. CSF spe-
cimens were centrifuged and fresh aliquots of the CSF
specimens were stored at -80°C. For analysis, these sam-
ples were slowly thawed on ice, centrifuged (10000 × g,
4°C, 15 min). Equal amounts of CSF protein (1.5 μg)
diluted with 9 volumes of washing buffer were applied
to each ProteinChip array spot. ProteinChip arrays were
then incubated in a humidity chamber at room tempera-
ture for 60 min with shaking at 200 rpm. Unbound pro-
teins were removed by washing three times for 5 min
with binding buffer and then briefly washed with HPLC
grade water. An energy absorbing molecule (EAM),
saturated sinapinic acid (SPA), in a solution containing
50% acetonitrile/5% trifluoroacetic acid, was applied to
the ProteinChip array spot surface. The arrays were air
dried and proteins captured on individual spots were
evaluated using the PBSIIc ProteinChip reader (Bio-
Rad). The ProteinChip reader was externally calibrated
with protein and peptide standards (Bio-Rad) containing
human angiotensin I (1296.5 Da), Fibrinopeptide B
(1570.6 Da), porcine Dynorphin A [209-225] (2147.5
Da), human ACTH [1-24] (2933.5 Da), human b-endor-
phin [61-91] (3465.0 Da), bovine insulin (5733.6 Da),
bovine Ubiquitin (8564.8 Da), bovine cytochrome-C
(12230.9 Da), bovine superoxide dismutase (15591.4
Da), equine myoglobin (16951.5 Da), bovine b-lactoglo-
burin A (18363.3 Da), horseradish peroxidase (43240.0
Da), bovine albumin (66410 Da), and chicken conalbu-
min (77490.0 Da) bovine IgG (147300.0 Da). External
calibration provided a 0.1% mass accuracy. The ionized
proteins were detected and their molecular mass/charge
(m/z) ratios determined using time-of-flight mass spec-
trometry (TOF-MS) analysis with a detection range m/z
of 1,570-12,230 for low molecular range, 5,733 to 43,240
for mid range and 16,951-147,300 for high molecular
range. The setting for cluster formation at the first pass
was set as S/N of 20% in all spectra, and for the second
pass S/N was set to 2%. The cluster mass window was
set to 0.3%. In one experiment, 713 peaks were identi-
fied. The protein concentration in CSF was determined
using Bradford methods (Bio-Rad) in a procedure con-
sistent with the manufacturer’s instructions.
Protein peaks were analyzed with the ProteinChip
Data Manager software version 3.0 (Bio-Rad). Each
study was repeated at least twice, with baseline subtrac-
tion, spectrum normalization, and peak detection per-
formed using the ProteinChip software.
Data collection and statistical methods
All spectra were externally mass calibrated and peak
intensities were normalized using total ion current. The
mean peak intensity of the duplicates was used for sta-
tistical analysis. Statistical analysis was also performed
using the Kruskal-Wallis H test. When differences were
significant, the Mann-Whitney U test was used to deter-
mine the significance of differences between each group.
Uncorrected p values were corrected by multiplying
them by the number of comparisons (Bonferroni-Dunn
correction) to calculate corrected p values.
Purification of the 4.8-kDa protein
Methodology for purifying the 4.8-kDa protein was
developed for on-chip analysis and also scaled up to col-
umn chromatography. First, conditions of capture were
defined using a combination of various binding/washing
buffers (100 mM sodium acetate, pH 4.0 and 5.0; 50
mM sodium phosphate, pH 6.0 and 7.0; and 50 mM
Tris-HCl, pH 8.0 and 9.0) and anion exchange (Q10)
and cation exchange (CM10) ProteinChip arrays. The
4.8-kDa protein was captured by Q10 ProteinChip
arrays with the pH 4.0-8.0 conditions. Then, 500 μlo fa
CSF sample was mixed with an equal volume of 50 mM
sodium acetate buffer (pH 4.0) containing 0.1% octyl
glucoside (Wako Chemicals, Osaka, Japan). A 100 μla l i -
quot of the mixture was passed through an anion
exchange column (Q Sepharose Fast Flow, GE Health-
care, Tokyo, Japan) and eluted with 50, 100, 200, 300,
500, and 1000 mM NaCl in 50 mM sodium acetate buf-
fer, pH 4.0 containing 0.1% octyl glucoside. Each reverse
phase fraction was analyzed for the presence of the 4.8-
kDa peak using NP20 ProteinChip arrays (Bio-Rad).
Protein species in reverse phase fractions were concen-
trated using micro-C18 ZipTip (Millipore, Billerica, MA,
USA) following manufacturer’s instructions, and reduced
and alkylated using iodoacetamide.
Peptide Mass Fingerprint (PMF) analysis of the 4.8-
kDa peak The 4.8-kDa peptide was subjected to peptide
mass fingerprinting (PMF) using ProteinChip arrays.
Briefly, purified species were applied onto a normal
phase ProteinChip array (NP20) and reduced with 5
mM DTT/10 mM NH4HCO3, (pH 8.0) at 70°C. Then, 2
μg/ml of trypsin (Promega, Tokyo, Japan) in 10 mM
NH4HCO3 (pH 8.0) was applied and incubated for 2 h
at 37°C. Digested peptides were detected using the Pro-
teinChip reader and the data were analyzed using the
Mascot search engine.
Identification of the 4.8-kDa peptide by MS/MS ana-
lysis For MS/MS analysis, the purified protein was
digested overnight with trypsin at 37°C, desalted with a
ZipTip (Millipore) eluted with 2 μl of an aqueous aceto-
nitrile solution (containing 50% acetonitrile (v/v) and
0.1% formic acid), and loaded onto a GlassTip in prepara-
tion for quadrupole time-of-flight (Q-TOF) MS analysis.
Q-TOF analysis was performed using a MALDI-QSTAR
mass spectrometer (Applied Biosystems, Tokyo, Japan)
operated in positive mode. The ions corresponding to the
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selected for subsequent collision-induced dissociation,
and the resultant fragment ions were analyzed. The
resulting MS/MS spectral information was submitted to
the Mascot search engine for identification. Among the
analyzed peaks, the m/z 1907 peak generated a good frag-
mentation pattern for the Mascot search. Search para-
meters and settings for the Mascot identification were as
follows: database (NCBInr), taxonomy (Homo sapiens),
enzyme (SemiTrypsin), fixed modification (none
selected), variable modification (Carbamidomethyl (C)),
peptide mass tolerance (± 0.3 Da), peptide tolerance (±
0.3 Da), MS/MS tolerance (± 0.15 Da), peptide charge
(+1), monoisotopic and max one missed cleavages. Sixty
one matching the ion was identified as gi|17136078, a
neurosecretory protein VGF precursor [Homo sapiens]
with score of 61 (score > 49 indicates identity) and gi|
2244659, a neuro-endocrine specific protein VGF [Homo
sapiens] with score of 61 (score > 49 indicates identity).
Results
Patient demographic analysis
For experiment 1, CSF samples were analyzed both from
patients with febrile seizure (n = 28) and with encepha-
lopathy (n = 8). There were no statistical differences
between the children with acute encephalopathy and
with febrile seizure in mean patient age, CSF cell num-
ber, total protein, or total sugar content (Table 1). For
experiment 2, there were also no statistical differences
in mean patient age, CSF cell number, total protein, or
sugar content between the patient groups (Table 1).
Experiment 1: Changes of CSF protein/peptide profiles in
febrile seizure patients compared to encephalopathy
patients
In the first set of experiments (experiment 1), protein/
peptide profiles of CSF samples were examined from 28
febrile seizure patients and eight encephalopathy
patients (Table 1) using SELDI-TOF mass spectrometry.
Fifteen peaks showed clear differences between febrile
seizure patients and encephalopathy patients (p < 0.05,
data not shown). Among these, six peaks had higher
intensity in patients with febrile seizures compared to
encephalopathy patients, and nine peaks were higher in
patients with encephalopathy compared to febrile sei-
zure patients (data not shown). Among these peaks, the
peak at m/z 4810 contributed the most to the separation
of the two groups (Figures 1, 2 and 3). Using the Krus-
kal-Wallis H test and the Mann-Whitney U test to com-
pare the mean signals from both groups, the mean
intensity of the m/z 4810 peak was found to be reduced
by 39% (p = 0.001).
Experiment 2
In experiment 2, the 15 candidate biomarkers from the
experiment 1 were analyzed using an independent, albeit
smaller, set of CSF samples from 14 febrile seizure
patients and five encephalop a t h yp a t i e n t s( T a b l e1 ) .
Among the 15 peaks which were identified in experi-
ment 1, 14 peaks were identified in experiment 2, but
only four peaks showed statistically significant differ-
ences (Figure 4 Table 2). Again, as in experiment 1, the
peak with an m/z of 4810 contributed the most to the
separation of the two groups (Figure 1, 2, 3 and 4).
Using the Kruskal-Wallis H test and the Mann-Whitney
U test to compare the mean peak intensity from both
groups, the mean intensity of the m/z 4810 peak was
reduced by 41% (p = 0.005).
Identification of the 4.8-kDa CSF peptide distinguishing
patients with febrile seizure from patients with
encephalopathy
The 4.8-kDa CSF protein species was purified using
anion ion exchange chromatography and reverse-phase
high-performance liquid chromatography. The 4.8-kDa
peak in the eluted fractions was detected using the Q10
ProteinChip array using the pH 8.0 binding/washing
buffer. The 4.8-kDa protein eluted in the 100 and 200
mM NaCl fractions. The 100 and 200 mM NaCl frac-
tions were purified by reverse phase high performance
Table 1 Demographics of subjects in CSF Experiment 1 and Experiment 2 sample sets
Age
(months)
Gender
(M/F)
Number of cells in CSF
(/ml)
Total protein in CSF
(mg/dl)
Total sugar in CSF
(mg/dl)
Experiment 1
Febrile seizure
(n = 28)
29.8 ± 24.9 20/8 1.2 ± 1.1 18.7 ± 8.0 84.5 ± 16.5
Encephalopathy
(n = 8)
46.4 ± 33.4 4/4 1.2 ± 1.0 22.9 ± 11.5 95.0 ± 43.4
Experiment 2
Febrile seizure
(n = 14)
44.1 ± 40.6 10/4 1.5 ± 1.5 18.8 ± 4.1 84.1 ± 14.3
Encephalopathy
(n = 5)
48.4 ± 38.5 3/2 3.0 ± 2.3 16.7 ± 6.0 76.3 ± 19.4
M/F: Male/Female.
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Toso, Tokyo, Japan). Fraction numbers 26 and 27
showed the 4.8-kDa peak protein and contained a pre-
dominant peak of 4.8 kDa between the 2000- to 10,000-
Da range by SELDI analysis (Figures 5 and 6, data not
shown). Protein species in reverse phase fractions 26
and 27 were concentrated and identified the protein by
tandem mass spectrometry (MS/MS) of tryptic peptides.
By single MS analysis, the m/z 1907 tryptic peptide was
selected for MS/MS fragmentation and identification
using the Mascot Search engine (Figure 7, 8). A Mascot
search was performed on the fragmentation pattern
from the 1907.8315 peak, and two protein candidates
containing the QNALLFAEEEDGEAGAED peptide were
identified, both with Mascot protein scores of 61.
Because the 4.8-kDa protein was digested with trypsin
to generate the m/z 1907 tryptic peptide, and the C-
terminal amino acid of the identified peptide was not
arginine or lysine as expected from trypsin cleavage, the
QNALLFAEEEDGEAGAED sequence is best explained
as the C-terminal region of the 4.8-kDa protein. This
sequence was matched with equal Mascot scores to
neurosecretory protein VGF precursor [Homo sapiens]
and neuro-endocrine specific protein VGF [Homo
sapiens]. With internal calibrants DynorphinA (2147.50)
and human insulin (5807.65), an exact mass of the can-
didate peak was determined to have an m/z of 4808.35.
Peptide mass fingerprint (PMF) analysis was used to
distinguish between the two protein candidates identi-
fied by MS/MS by comparing predicted tryptic peptides
less than 4.8 kDa with QNALLFAEEEDGEAGAED as
the C-terminal sequence. MS of the tryptic digest
revealed an m/z 4280 peak as predicted from the neuro-
secretory protein VGF precursor sequence, and no m/z
4337 peak as predicted from neuro-endocrine specific
protein VGF sequence (Figure 9). It was therefore con-
cluded that the 4.8-kDa protein is a proteolytic frag-
ment of the neurosecretory protein VGF precursor
(Figure 10).
Discussion
Acute encephalopathy leads to rapid deterioration and a
poor prognosis with neurologic complications. For
detection of an early diagnostic marker for acute ence-
phalopathy, SELDI-TOF MS was employed to identify
possible biomarker candidates for acute encephalopathy
in cerebrospinal fluid. A 4.8-kDa proteolytic peptide
fragment from the protein of a neurosecretory protein
VGF was identified as a novel biomarker for encephalo-
pathy (VGF4.8). From previous literature, other peaks
differentially expressed in the experiments in the present
study were suggested to be: the double charge of Trans-
thyretin (m/z 6880), which has neuroprotective func-
tions [10]; Ubiquitin (m/z 8564), which is known to be
involved in targeting proteins for degradation [11]; and
Cystatin C 1-8 a truncated form (m/z 12536), which is a
cysteine protease inhibitor and plays an important role
in regulating extracellular protein homeostasis in the
CNS [10,12]. The identification for these peaks is
underway.
VGF4.8 and other similar VGF peptides have been
reported in Alzheimer’s disease [11,13-15], amyotrophic
lateral sclerosis (ALS) [16], and frontotemporal demen-
tia [17]. Carrette et al reported that VGEE-
DEEAAEAEAEAEEAER peptide, which was between the
aminoacid 378 to 397 of neurosecretory protein VGF
precursor, from the CSF in Alzheimer’s disease [13].
This sequence was identical to our identified peptide
sequence of VGF protein (Figure 10: double underline).
The VGF4.8 peptides in CSF are decreased compared
with normal controls in diseases such as Alzheimer’s,
ALS, and frontotemporal dementia. These diseases
showed pathologically degenerative changes as well as
encephalopathy, which were specifically investigated in
this study. Thus, the VGF4.8 peptide might be a novel
marker for degenerative brain conditions with encepha-
lopathy in children.
Figure 1 Gel view of SELDI-TOF MS proteomic spectra of CSF
from patients with febrile seizure and patients with
encephalopathy. Protein/peptide profiles of CSF samples were
examined from 28 febrile seizure patients and eight encephalopathy
patients using SELDI-TOF mass spectrometry. Because samples were
measured in duplicate, a set of two gel views from one patient
were provided.
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regulated transcript in rat PC12 pheochromocytoma cells
[16]. In vivo, the VGF mRNA and its encoded protein are
selectively synthesized in neuroendocrine and neuronal
cells. VGF is regulated by neuronal activity, including long-
term potentiation, seizure, injury [13] and aging [18].
Brain-derived neurotrophic factor (BDNF) and NT-3 can
also regulate the expression of VGF in cortical neurons
[13]. In Alzheimer’s disease, the BDNF mRNA is decreased.
This decrease could result in a decrease of synthesis of the
Figure 3 SELDI-TOF MS intensities of the m/z 4810 peak from experiments 1 and 2. Experiment 1: The mean intensity of the m/z 4810
peak was reduced by 39% (p = 0.001) in encephalopathy patients compared to patients with febrile seizures. Experiment 2: The mean intensity
of the m/z 4810 peak was reduced by 41% (p = 0.005) in encephalopathy patients compared to patients with febrile seizures. FS: febrile seizure,
Enc: encephalopathy.
Figure 2 Representative data of SELDI-TOF MS proteomic spectra of CSF from patients with febrile seizure and patients with
encephalopathy.
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ALS and frontolateral dementia, progression of neuronal
damage probably causes a decrease of neuronal products of
VGF and loss of their protective function [14].
T h ep r i m a r yV G Fg e n ep r o d u c ti sp r o c e s s e db y
endoproteolytic cleavages, resulting in a range of VGF
peptides [16]. To date, 10 rat VGF peptides and three
human VGF peptides have been identified [16]. The
VGF4.8 sequence, which was obtained in this study, is
rich in paired basic amino acid residues that are
potential sites for proteolytic processing or sequence
motifs of adjacent basic amino acids (arginine and/or
lysine) as potential recognition sites for processing by
prohormone convertases [14]. The modified com-
pounds described in the present study are very likely
biologically active and not merely incidental fragments
[14].
It can be speculated that either deficiencies of neuro-
trophic factors or increased neurotrophic consumption in
encephalopathy might lead to reduced levels of VGF [16].
Because VGF is essential for feeding behavior and energy
expenditure, an enormous number of possible mechanisms
Figure 4 Scatter plots for differentially expressed peaks in experiments 1 and 2. Four peaks (m/z 3874, 4810, 6874, and 12526) showed
significant difference in the mean intensity between encephalopathy patients and febrile seizure patients.
Table 2 Differentially expressed peaks
Peak
(m/z)
Protein Chip
Array Type
Level in
encephalopathy
p-value of encephalopathy vs. febrile
seizure (Experiment 1)
p-value of encephalopathy vs. febrile
seizure (Experiment 2)
3874 Q10 Low 0.04 0.05
4810 Q10 Low 0.001 0.005
6874 CM10 High 0.03 0.01
12526 CM10 Low 0.005 0.001
Asano et al. BMC Neurology 2011, 11:101
http://www.biomedcentral.com/1471-2377/11/101
Page 7 of 11Figure 5 Purification of the 4.8-kDa biomarker candidate using HPLC. The 4.8-kDa protein eluted from the Q Sepharose Fast Flow anion
exchange column in the 100 and 200 mM NaCl fractions. The 200 mM NaCl fraction eluted from the Q Sepharose Fast Flow anion exchange
column was further purified by reverse phase HPLC.
Figure 6 Confirmation of the single peak in the 2000 to 10,000 Da range. Each reverse phase fraction was analyzed by SELDI using NP20
ProteinChip arrays to detect the 4.8-kDa peak. It was confirmed that fractions 26 and 27 contained a predominant peak at 4.8 kDa in the 2000
to 10,000 Da range using NP20 ProteinChip arrays and SELDI analysis.
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Page 8 of 11Figure 7 MS analysis of the trypsin digest of the purified protein. The purified protein was digested overnight with trypsin at 37°C and
desalted in preparation for Q-TOF MS analysis. Q-TOF analysis was performed using a MALDI-QSTAR. The ions corresponding to the tryptic
digest peptides from the 4810 m/z species were selected for subsequent collision-induced dissociation and the resultant fragment ions were
analyzed. The resulting MS/MS spectral information was submitted to the Mascot search engine for identification. Among the analyzed peaks,
the m/z 1907 peak generated a good fragmentation pattern for the Mascot search.
Figure 8 Collision-induced dissociation spectrum for the ion with m/z of 1907. The major individual peaks are assigned to a-, b, or y-type
ions of di- or tri-peptide fragments.
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Page 9 of 11whereby a deficiency of VGF might contribute to encepha-
lopathy susceptibility or modify the phenotype of the clini-
cal syndrome of encephalopathy are possible.
Conclusions
We found a 4.8-kDa peptide fragment from a neurose-
cretory protein VGF precursor (VGF4.8) in CSF was
identified as a novel biomarker for encephalopathy using
Surface-enhanced laser desorption/ionization time-of-
flight mass spectrometry (SELDI-TOF MS). Expression
of VGF4.8 has been reported to be decreased in patho-
logically degenerative changes such as Alzheimer’sd i s -
ease, amyotrophic lateral sclerosis (ALS), and
frontotemporal dementia. Thus the VGF4.8 peptide
Figure 9 Peptide Mass Fingerprint (PMF) analysis of the purified 4.8-kDa protein. PMF analysis was used to distinguish between the two
protein candidates identified by MS/MS. Spectrum data and sequences were obtained from the peptides digested by trypsin. The MS of the
tryptic digest contained an m/z 4280 peak as predicted from the neurosecretory protein VGF precursor [Homo sapiens] sequence, and no m/z
4337 peak as predicted from the neuro-endocrine specific protein VGF [Homo sapiens] sequence.
Figure 10 Sequence of amino acids in neurosecretory protein VGF precursor [Homo sapiens]. Bold: neurosecretory protein VGF(23-615).
Red characters: MS/MS analysis (400-417, 1907.9 m/z)). Underline: analysis (373-417, 4808.8 m/z). Double underline: Carrette et al. (ref 13)
confirmed 378-397 sequence from 4.8 kD peptide.
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tions. Further investigation into VGF4.8 could provide
insight into the mechanism of encephalopathy as well as
possible treatment strategies.
List of abbreviation
ALS: amyotrophic lateral sclerosis; BDNF: brain derived neurotrophic factor;
CSF: cerebrospinal fluid; EAM: energy-absorbing molecule; HPLC: reverse-
phase high-performance liquid chromatography; MS: mass spectrometry; m/
z: mass/charge ratio: NGF: nerve growth factor; PMF: peptide mass
fingerprint; SELDI-TOF MS: surface-enhanced laser desorption/ionization
time-of-flight mass spectrometry; SPA: saturated sinapinic acid; and VGF4.8: a
4.8-kDa proteolytic peptide fragment of neurosecretory protein VGF
precursor.
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